<DOC>
	<DOCNO>NCT02844075</DOCNO>
	<brief_summary>In study , participant esophageal squamous cell carcinoma receive preoperative chemoradiotherapy paclitaxel , carboplatin pembrolizumab undergo surgery . The primary study hypothesis add pembrolizumab increase complete pathologic response rate surgery .</brief_summary>
	<brief_title>A Phase II Trial Preoperative Chemoradiotherapy MK-3475 Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Histologically confirm ESCC 2 . Clinical stage T1N12 T234aN012 ( AJCC 7 TNM classification ) 3 . No evidence metastasis 4 . Be willing able provide write informed consent/assent trial . 5 . Be 20 year age day sign informed consent . 6 . Be willing provide tissue newly obtain core excisional biopsy tumor lesion repeat biopsy . Newlyobtained defined specimen obtain 6 week ( 42 day ) prior initiation treatment Day 1 . Subjects newlyobtained sample provide ( e.g . inaccessible subject safety concern ) may submit archived specimen upon agreement Sponsor . 7 . Have performance status 0 1 ECOG Performance Scale . 8 . Demonstrate adequate organ function define Table 1 , screen lab perform within 10 day treatment initiation . 9 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 10 . Female subject childbearing potential ( Section 5.7.2 ) must willing use adequate method contraception outline Section 5.7.2 Contraception , course study 120 day last dose study medication . Note : Abstinence acceptable usual lifestyle prefer contraception subject . 11 . Male subject childbearing potential ( Section 5.7.1 ) must agree use adequate method contraception outline Section 5.7.1 Contraception , start first dose study therapy 120 day last dose study therapy . 1 . Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has know history active TB ( Bacillus Tuberculosis ) 4 . Hypersensitivity pembrolizumab excipients . 5 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 7 . Has another malignancy within last 5 year . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative surgery , situ cervical cancer . 8 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 9 . Has know history , evidence active , noninfectious pneumonitis . 10 . Has active infection require systemic therapy . 11 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 12 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 13 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 14 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 15 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 16 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 17 . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Esophageal Squamous Cell Carcinoma</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>PD-1</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>chemoradiation</keyword>
</DOC>